References
- Yuan J, Jiang Q, Song L, et al. L-carnitine is involved in hyperbaric oxygen-mediated therapeutic effects in high fat diet-induced lipid metabolism dysfunction. Molecules 2020;25:176.
- Xu X, Ni H, Guo Y, et al. Hexafluoropropylene oxide dimer acid (HFPO-DA) induced developmental cardiotoxicity and hepatotoxicity in hatchling chickens: roles of peroxisome proliferator activated receptor alpha. Environ Pollut 2021;290:118112.
- Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a huge association review. Am J Epidemiol 2004;160:421–9.
- Wadhera RK, Steen DL, Khan I, et al. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol 2016;10:472–89.
- Seidah NG. Pcsk9 as a therapeutic target of dyslipidemia. Exp Opin Ther Targets 2009;13:19–28.
- Qian YW, Schmidt RJ, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007;48:1488–98.
- Xu ST, Luo SS, Zhu ZY, Xu JY. Small molecules as inhibitors of PCSK9: current status and future challenges. Eur J Med Chem 2019;162:(212–33.
- Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489–99.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–22.
- Navarese EP, Kołodziejczak M, Schulze V, Sr, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163:40–51.
- Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;4:CD011748.
- Katzmann JL, Gouni-Berthold I, Laufs U. PCSK9 inhibition: insights from clinical trials and future prospects. Front Physiol 2020;11:595819.
- Chen B, Shi X, Cui YP, et al. A review of PCSK9 inhibitors and their effects on cardiovascular diseases. Curr Top Med Chem 2019;19:1790–817.
- Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol 2019;16:155–65.
- Taechalertpaisarn J, Zhao B, Liang X, Burgess K. Small molecule inhibitors of the PCSK9.LDLR interaction. J Am Chem Soc 2018;140:3242–9.
- Lammi C, Sgrignani J, Arnoldi A, et al. Computationally driven structure optimization, synthesis, and biological evaluation of imidazole-based proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors. J Med Chem 2019;62:6163–74.
- Lammi C, Sgrignani J, Roda G, et al. Inhibition of PCSK9(D374Y)/LDLR protein-protein interaction by computationally designed T9 lupin peptide. ACS Med Chem Lett 2019;10:425–30.
- Evison BJ, Palmer JT, Lambert G, et al. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove. Bioorg Med Chem 2020;28:115344.
- Min DK, Lee HS, Lee N, et al. In silico screening of chemical libraries to develop inhibitors that hamper the interaction of PCSK9 with the LDL receptor. Yonsei Med J 2015;56:1251–7.
- Stucchi M, Grazioso G, Lammi C, et al. Disrupting the PCSK9/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic. Org Biomol Chem 2016;14:9736–40.
- Lammi C, Sgrignani J, Arnoldi A, et al. Computationally driven structure optimization, synthesis, and biological evaluation of imidazole-based proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors. J Med Chem 2019;62:6163–74.
- Fan W, Zhang L, Wang X, et al. Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps. J Enzyme Inhib Med Chem 2021;36:707–18.